Laurus Labs Q1FY22 net profit surges 40% to Rs 241 crore, led by anti-HIV formulation sales – Moneycontrol.com

The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus’ EBITDA margins were down by 250 basis points. Read More